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S U M M A R Y
Background: Risk factors for colonization with vancomycin-resistant enterococci (VRE) vary by
population and locale. The objective of this study was to determine the prevalence of and risk factors
for VRE colonization in children with acute lymphoblastic leukemia (ALL) in Tehran.
Methods: Stools were collected from children with ALL at the Ali Asghar Children’s Hospital and the
Mahak Pediatric Oncology Center between March 2007 and October 2008. Demographic features and
potential risk factors for VRE colonization, including duration of ALL, presence of severe neutropenia in
the preceding month, receipt of antibiotics in the preceding 3 months, concurrent medical problems,
days of hospitalization, and the need for intensive care since the time of diagnosis of ALL, were recorded.
Results: VRE was identiﬁed from stools in 33 of 130 children with ALL (25%). No clear risk factors were
identiﬁed for VRE colonization in the current study, but there was a trend towards an increased
prevalence in children admitted to the intensive care unit since their ALL diagnosis (p = 0.07). The VanA
genotype was found in 28 of the 33 stools (85%), with all other enterococci being VanB.
Conclusions: The prevalence of VRE colonization in children with ALL in Tehran is high. Modiﬁable risk
factors have not been identiﬁed. The implementation of routine surveillance for colonization and an
increased emphasis on adherence to standard infection control precautions may prevent spread.
 2011 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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Glycopeptide resistance in enterococci was ﬁrst reported in
Europe in 1986 and in the USA in 1987.1 Vancomycin inhibits the
late stages of cell wall synthesis by binding to peptidoglycan
precursors. Resistance in Enterococcus occurs because of altered
peptidoglycan precursors with a decreased afﬁnity for vancomy-
cin. Acquired resistance in human isolates usually implies the
presence of the vanA or vanB ligase gene. High-grade resistance
(minimum inhibitory concentration (MIC) 16mg/ml) is more
frequent in Enterococcus faecium than in Enterococcus faecalis and is
usually attributable to VanA.2
An alarming 34-fold increase in the incidence of vancomycin-
resistant Enterococcus (VRE)-related nosocomial infections was
reported in intensive care units (ICU) in the USA between 1989 and
1993.1 Since then, attempts have been made to prevent the spread
of colonization in high-risk patients, including thosewith cancer or
chronic hematological diseases, as colonization often precedes* Corresponding author. Tel.: +1 780 407 3666; fax: +1 780 407 7136.
E-mail address: jr3@ualberta.ca (J.L. Robinson).
1201-9712/$36.00 – see front matter  2011 International Society for Infectious Disea
doi:10.1016/j.ijid.2011.01.006infection.1 It appears that risk factors for VRE colonization vary in
different geographical areas. For example, selective pressure due to
excessive use of vancomycin and/or third-generation cephalos-
porins has been found to be a risk factor for VRE colonization in
some studies,3,4 but not in another.5 Therefore, it is useful to clarify
the risk factors for VRE colonization in speciﬁc patient groups
when designing local strategies to prevent spread.
Previously recognized risk factors for VRE colonization in
children include young age,6 the use of speciﬁc antibiotics6,7 or
chemotherapy,6 and the presence of indwelling medical devices
such as feeding tubes.6 Apparent nosocomial spread has been
documented.8
The objectives of this studywere to determine the prevalence of
VRE colonization, the risks for colonization, and the genotypic
features of VRE isolates in children with acute lymphoblastic
leukemia (ALL), the most common cancer, in two tertiary pediatric
referral centers in Tehran.
2. Methods
A prevalence study was performed of children aged up to
18 years currently on treatment for ALL at the Ali Asghar Children’sses. Published by Elsevier Ltd. All rights reserved.
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an oncology outpatient clinic) and the Mahak Pediatric Oncology
Center (a 120-bed oncology hospital with an outpatient clinic),
fromMarch 2007 to October 2008. Routine screening for VRE is not
performed at these hospitals, but patients are placed on contact
precautions (gloves with all contact and masks for very close
contact) if VRE colonization or infection is detected.
Parents of all eligible childrenwere approached about the study
at their next clinic visit or hospitalization, once the study had
started. A fresh stool sample was obtained from each child at the
ﬁrst available opportunity, in the inpatient or outpatient setting,
after informed consent was obtained. Stool samples were rapidly
submitted to the Pediatric Infectious Diseases Research Laboratory
at Moﬁd Children’s Hospital.
2.1. VRE detection
The samples were inoculated onto Enterococcosel agar after
24 h of incubation at 37 8C. Isolates were conﬁrmed to be
enterococci by Gram stain, pyrrolidonyl arylamidase activity,
motility, and catalase, and were then subcultured onto three
culture media: (1) Mueller–Hinton agar to determine their growth
at 15 8C and 45 8C, (2) NaCl 6.5%, and (3) bile esculin agar
containing 6mg/ml vancomycin and 64 mg/ml ceftazidime for
screening for resistance. Allmediawere kept at 37 8C for 24 h. After
15–48 h of incubation at 37 8C, suspensions of presumptive VRE
colonies were prepared to a density equivalent to a McFarland
standard of 3 in 50 ml of 7.5% Chelex 100 in preparation for DNA
extraction. All Enterococcus species were then frozen and kept
at  85 8C until DNA extraction and PCR was performed to
determine VRE genotype.
2.2. DNA extraction from specimens
The bacterial culture was centrifuged at 7500  g for 10 min.
Then 100ml protease buffer was added to the pellets. After
incubation at 95 8C for 10 min, 400 ml lysis buffer and 300 ml of
precipitation solution were added to 100ml of the sample. Then,
after incubation at 20 8C for 20 min, the solution was mixed with
200 ml of equilibrated phenol and centrifuged at 8000  g for
5 min. The supernatant was then mixed with 200ml chloroform
and centrifuged again at 8000  g for 5 min. DNA was precipitated
with 400ml absolute ethanol and 2 M sodium acetate at20 8C for
1 h. After drying the tubes, DNAwas precipitated againwith 100ml
70% ethanol at20 8C for 1 h and then dissolved in 50 ml TE buffer.
We used a PCRmaster kit (catalog No. PR8250; Cinagene Company,
Iran) for detection of Enterococcus DNA.
2.3. Polymerase chain reaction
The multiplex ampliﬁcation reaction was performed in a
volume of 50 ml and contained: 1.2 U Taq-DNA polymerase, 1ml
extracted DNA, 0.2 mM dNTP, 2.5 mM MgCl2, 50 pmol of each
primer, and 1  PCR mix (Table 1). The reaction was run for 35
cycles under the following conditions: 60 s at 94 8C, 20 s at 61 8C,
and 120 s at 50 8C for VanA or 60 8C for VanB (since VanB wasTable 1
Primer speciﬁcity for vancomycin genes in enterococci isolated from stools of
children with leukemia.
Primer speciﬁcity Size of PCR
product (bp)
Primer pair sequences
vanA 1030 50-CATGAATAGAATAAAAGTTGCAATA-30
5-CCCCTTTAACGCTAATACGATCAA-30
vanB 433 50-GTGACAAACCGGAGGCGAGGA-30
5-CCGCCATCCTCCTGCAAAAAA-30detected better at the higher temperature). After the last cycle, a
ﬁnal extension of 5 min at 72 8C was performed to complete the
synthesis. Ampliﬁcation products were visualized and photo-
graphed under UV light after electrophoresis for 45 min at 100 V
through a 1.5% agarose gel, containing ethidium bromide. VanB
and VanB2/B3 could not be differentiated with this method.
At the time of sample submission, demographic features and
potential risk factors for VRE colonization, including the duration
of ALL, presence of severe neutropenia (absolute neutrophil count
0.1  109/l) in the preceding month, receipt of antibiotics in the
preceding 3 months, concurrent medical problems (deﬁned as any
seriousmedical problemunrelated to ALL), and the number of days
of hospitalization (including bothward and ICU days) and the need
for intensive care since the time of diagnosis of ALL, were obtained
from chart review or parental interview. This study was approved
by the research ethics boards of the Iran University of Medical
Sciences and the Pediatric Infectious Diseases Research Laboratory
at Moﬁd Children’s Hospital.
2.4. Statistics
The prevalence of VRE colonization in patients with cancers has
been investigated in previous studies, indicating an approximate
endemic rate of 5%.9 Therefore, a sample size of 75 patients would
yield the colonization rate  2.5%. Because of uncertainty with
regard to the expected colonization rate, this sample size was
deliberately exceeded. Comparisons of risk factors were made by use
of the Student’s t-test or Mann–Whitney test, as appropriate. A p-
value of 0.05 was considered to be statistically signiﬁcant.
3. Results
3.1. VRE colonization
One-hundred thirty children (81 males, 49 females) participat-
ed in the study. Another 10 eligible children were excluded as
consent was not obtained or stool was not submitted. The VRE
status was not known for any of the children prior to enrollment.
Themean age of enrolled patientswas 6.5 years (range 6months to
16.5 years). The mean duration of ALL at the time of enrollment
was 16.5 months (range 0 to 126 months; standard devia-
tion = 22.7 months). Fifty-four percent of cases had been admitted
to hospital more than 10 times since their ALL diagnosis. In the
month prior to enrolment, 58% of cases had a documented severe
neutropenia. Sixty-ﬁve percent of cases had received systemic
antibiotics in the 3 months preceding enrollment, with the most
common antibiotics being ceftriaxone, ceftazidime, amikacin,
ceﬁxime and co-trimoxazole, in order of frequency. About one-
third of antibiotic courses were intravenous and two-thirds oral.
Ninety-ﬁve of 130 stool samples were positive for Enterococcus
species (73%) of which 33 were resistant to vancomycin, yielding a
VRE colonization rate of 25%.
3.2. Risk factors for VRE colonization
Table 2 shows the analysis of the possible risk factors for VRE
colonization. There was a trend towards an increased incidence of
ICU admissions in patients with VRE, but no other risk factors were
apparent.
The most common phenotype was VanA (n = 28; 85%), with all
other isolates having the VanB phenotype. An analysis of
phenotypes against risk factors (Table 3) showed that children
with VanA were older than those with VanB (7.0 years vs.
4.1 years; p = 0.007). No other differences were noted between
children with the two phenotypes. None of the enrolled children
developed a VRE infection during the study period.
Table 2
Risk factors for carriage of vancomycin-resistant enterococci in children with acute lymphoblastic leukemia.
Risk factor Colonized with
VRE (n=33)
Not colonized with
VRE (n=97)
p-Value
Age, mean SD (IQR) years 6.43.9 (4.4–7.8) 6.53.7 (4.0–7.5) 0.99
Male, n (%) 24 (73%) 59 (61%) 0.23
Duration of leukemia, mean SD months 1324 1822 0.3
History of severe neutropenia during the month prior
to enrollment (ANC 0.1109/l), n (%)
21 (64%) 54 (56%) 0.54
Concurrent medical problems 3 (9%) 10 (10%) 1
Received oral or intravenous antibiotics during the
3 months prior to enrollment, n (%)
25 (76%) 62 (64%) 0.28
Vancomycin 9 (27%) 18 (19%) 0.28
Third-generation cephalosporins 14 (42%) 40 (41%) 1.0
Others 25 (76%) 54 (56%) 0.06
Days of hospitalization on ward or in ICU since diagnosis
of ALL, mean SD
37.830.3 34.016.4 if not colonized
with enterococci, 33.722.6
if colonized with VSE
0.90 for VRE colonized
versus VSE colonized
Total number of hospital admissions since diagnosis of ALL, mean SD 6.404.69 6.113.38 0.74
History of ICU admission since diagnosis of ALL, n (%) 6 (18%) 6 (6%) 0.07
ALL, acute lymphoblastic leukemia; ANC, absolute neutrophil count; ICU, intensive care unit; IQR, interquartile range; SD, standard deviation; VRE, vancomycin-resistant
Enterococcus; VSE, vancomycin-susceptible Enterococcus.
Table 3
Risk factors for carriage of vancomycin-resistant enterococci with different phenotypes in children with acute lymphoblastic leukemia.
Risk factor Carriers of VanA (n=26) Carriers of VanB (n=7) p-Value
Age, mean SD (IQR) years 7.03.7 (4.0–9.4) 4.11.7 (3.5–5.1) 0.007
Male, n (%) 17 (65%) 7 (100%) 0.14
Duration of leukemia, mean SD months 13.425.4 10.916.8 0.8
History of severe neutropenia during the month prior to enrollment (ANC 0.1109/l), n (%) 17 (65%) 4 (57%) 0.68
Concurrent medical problems 2 1 0.52
Received oral or intravenous antibiotics during the 3 months prior to enrollment, n (%) 19 (73%) 4 (57%) 0.64
History of ICU admission since diagnosis of ALL, n (%) 4 (15%) 2 (29%) 0.58
ALL, acute lymphoblastic leukemia; ANC, absolute neutrophil count; ICU, intensive care unit; IQR, interquartile range; SD, standard deviation.
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To our knowledge this is the ﬁrst study of VRE colonization in
children with ALL in Iran, showing one-quarter of those with ALL to
be colonized. Worldwide, there are limited studies addressing the
problem of VRE colonization in the pediatric age group. A recent
study from a teaching hospital in the neighboring country of Turkey
showed just 36 of 2488 rectal swabs performed for routine pediatric
VRE screening to be positive (1.5%); all were VanA.8 A study
performed in a pediatric ICU in the USA in 2007 and 2008 showed
only 30 of 981 children screened with rectal swabs to have VRE
colonization (3%),with another 19children (2%)havingpossibleVRE
colonization as they had VRE isolated from other sites within 3 days
of admission (n = 2) or had a history of previous VRE colonization
(n = 17).10 Another study from the USA showed that ﬁve of 52
children on an oncology ward (10%) with no known history of VRE
colonization, were positive on stool samples or rectal swabs when
surveyed in 2006.7 A colonization rate similar to that found in our
studywas reported in thepediatrichematology–oncologywardsof a
US hospital in 1994 (24%; in rectal swabs), with all isolates being E.
faecium.6 However, this study was precipitated by an outbreak of
invasive VRE infection; no such outbreakwas recognized at either of
the hospitals in the current study.
No clear risk factors were identiﬁed for VRE colonization in the
current study, but there was a trend towards an increased
prevalence in children admitted to the ICU since their ALL
diagnosis (p = 0.07). Such patients would be predicted to be at
risk, as they typically receive long courses of broad-spectrum
antibiotics, undergo many invasive procedures (a risk factor that
was not speciﬁcally analyzed in the current study), and are cared
for in overcrowded settings where hand hygiene and isolation
practices may be suboptimal. A study in adults showed thatprolonged ICU admission was a risk factor for VRE colonization.11
Because of the small number of ICU admissions in total (N = 6), we
did not look at the duration of ICU admission as a risk factor. A
study of children admitted to a US pediatric ICU identiﬁed previous
admission to the same institution within the preceding 12 months
to be a risk factor for VRE colonization,10 but that factor could not
be analyzed in the current study as almost all children would have
had a hospitalization in the preceding 12 months. However, there
was no correlation between VRE colonization and the number of
hospitalizations or total days in hospital since diagnosis in the
current study.
Although previous antibiotic usage has been considered to be a
risk factor for VRE colonization,6,10–13 the current study did not
clearly show such an association. This is somewhat surprising as
inappropriate usage of antibiotics, especially vancomycin, is quite
common in our setting.14 Possible explanations would include
differences in hygiene practices, such that person-to-person
spread is a more important factor than is the use of antibiotics.
Other possibilities would be that ethnic or geographic differences
alter the enteric microﬂora. In terms of risk with speciﬁc
antibiotics, previous studies have shown prior use of vancomy-
cin,3,6,12 third-generation cephalosporins,4,6,15,16 broad-spectrum
antibiotics,5,17 or antibiotics that cover anaerobes4,16 to be risk
factors for VRE colonization,while amodeling study has also linked
new acquisition of VRE colonization to the use of ﬂuoroquino-
lones.18 The use of vancomycin or the use of third-generation
cephalosporins in the preceding 3 months were not risk factors for
VRE colonization in the current study, but there was a trend
towards the use of ‘other’ antibiotics in patients with colonization
(p = 0.06). Neutropenia has been found to be a risk factor for VRE
colonization in previous studies;19 it may be amarker for the use of
broad-spectrum antibiotics or vice versa.
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showed younger age to be a risk factor for VRE colonization.6 Age
was not a risk factor in the current study, although older children
weremore likely to have the VanA genotype. Onemight expect the
duration of malignancy to be associated with a higher colonization
rate. This has not been previously studied and did not appear to be
a risk factor in the current study. Duration of the current
hospitalization has been shown to be a risk factor in previous
studies,17 but was not applicable in the current study as many of
the samples were from the outpatient setting. The presence of a
concurrent medical illness has also been considered a risk factor in
some,3,11,17 but not in other studies;6,7 this was not a risk factor in
the current study, but deﬁnitions vary from study to study and very
few children had concurrent medical problems in our study.
The explanation for the high VRE colonization rate in this study
is not clear. There have been no previous or subsequent studies of
VRE colonization in either hospital, so rates cannot be compared to
historic rates or to those in children in these hospitals with
diagnoses other than ALL. Rectal thermometers are rarely used in
oncology patients in the study hospitals, as patients are usually
neutropenic. No other nosocomial source has become apparent. A
recent study in an adult hospital in Tehran showed that 1.4% of
newly admitted patients vs. 7.5% of patients admitted for a
minimum 48 h or on chronic hemodialysis were colonized with
VRE.20 Sub-standard infection control practice in hospitals is
undoubtedly an important risk factor.
Limitations of this study include the fact that not all eligible
patients were included, hence it is not truly population-based. It
would have been useful to analyze serial stool cultures to
determine the natural history of VRE colonization in this
population. Collecting antibiotic data for the period since the date
of diagnosis rather than just for the preceding 3monthsmight have
clariﬁed the relationship between antibiotic use and VRE
colonization. Had the study population been larger, it would also
have been useful to determine risk factors for invasive diseasewith
VRE. A large case–control study should be considered in the future.
5. Conclusions
Although serious enterococcal infections have not been
common in our high-risk pediatric patients, the unexpectedly
very high rate of VRE colonization needs to be addressed. Clearance
of carriage is difﬁcult to achieve. Therefore, the most important
preventive measure would be to improve standard infection
control precautions such as hand hygiene and decontamination of
fomites, particularly in ICUs. Auxiliary measures such as routine
screening for VRE colonization and isolation of known carriers in
subsequent admissions should also be stressed if an increase in the
rate and future devastating infections are to be avoided.
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